Adding measures of patients' symptoms, signs, and functions into brain tumor clinical trials will ultimately improve patient care. But first, doctors, researchers, drug makers, and the FDA must fully understand what matters most to patients. To get this critical insight to stakeholders in the drug development and approval process, the National Brain Tumor Society distributed a survey to brain tumor patients, caregivers, and families because the most important voice in this effort is yours. These researchers, companies, and regulators need to know what patients want in terms of treatment options. Clearly, living longer and finding a cure is our number one priority. But, there may be treatments that reduce symptoms or improve quality of life, and those treatments should be evaluated through the clinical trial process, as well.

We thank everyone who took our Survey to help inform these stakeholders in brain tumor drug development, and as promised, are sharing some of our early findings back with the community in this new infographic.

"Immunotherapy" is one of the hot topics in cancer research right now. To help us and our community understand more about immunotherapies - what they are, how they works, promises, and challenges - we reached out to one of the leading experts in brain tumor immunotherapy, Dr. John Sampson from Duke University, who kindly dedicated his time for a two-part Q&A. Read More

National Brain Tumor Society has been awarded the top rating of four stars from the leading independent charity review source, Charity Navigator. This rating designates the National Brain Tumor Society as an "exceptional" nonprofit and indicates that the Organization is in an exclusive category, as only 25% of the organizations that Charity Navigator reviews receive the full four-star rating. Read More